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OBJECTIVE: Proton pump inhibitors (PPIs) are an effec-
tive and safe treatment for healing GERD-related reflux
esophagitis. What remains unclear is whether there are
significant clinical and economic differences between the
PPIs for this type of indication. We conducted an eco-
nomic analysis comparing the newer PPIs to standard ref-
erence treatments based on the most commonly pre-
scribed PPI (omeprazole) and H2-blocker (ranitidine).
METHODS: We combined relative-healing-rate data
taken from a meta-analysis of head-to-head studies, with
similarly published data for omeprazole and ranitidine.
Using wholesale drug prices, we considered the difference
in treatment cost and success for each PPI compared to
omeprazole and ranitidine. Sensitivity analyses were con-
ducted using 95% confidence intervals around relative ef-
fect sizes and treatment failure costs.
RESULTS: Esomeprazole was the only PPI with statis-
tically significant differences to omeprazole, with 24 ad-
ditional healings per 1000 treated patients, at a cost per
additional healing of US$340. Introducing additional
costs, of over US$600 linked to managing treatment fail-
ures, resulted in esomeprazole dominating omeprazole.
Lansoprazole also showed additional benefit with a
lower cost, but failed to reach significant levels. Panto-
prazole and rabeprazole had slightly less treatment suc-
cess with a lower cost, but again confidence intervals
were wide. Compared to H2-blockers, all PPIs provided
significant additional benefits at a cost per healed patient
of US$200 to US$600, depending on the form of H2-
blocker. PPIs dominated once treatment-failure costs
were included.
CONCLUSION: Our study shows that over an eight-
week treatment period, esomeprazole is the only PPI that
is significantly distinguished from omeprazole in terms of
its clinical and economic effects. Our analysis also sug-
gests that PPI treatment is cost-effective compared to H2-
blockers, irrespective of the choice of PPI. Importantly,
omeprazole is soon to go off patent, and this is likely to
significantly reduce the incremental cost-effectiveness of
the newer PPIs.
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THE IMPACT OF THE USE OF NEXIUM ON THE 
OVERALL PPI BUDGET IN GREECE
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OBJECTIVES: Pharmaceutical spending control is a ma-
jor objective for most governments. The introduction of
new drugs is considered as a reason for increased spend-
ing, although often leading to actual savings. This study
aims to evaluate the effect that market penetration of es-
omeprazole (Nexium) will have on PPI pharmaceutical
expenditures in Greece.
METHODS: A model estimating drug budget savings po-
tentially achieved by replacing other PPIs with Nexium in
the Greek market has been developed based on clinical
trial results and market research data. This model is
based on current (MAT/5/2001) PPI sales data (IMS
data). For every marketed PPI, a “replacement ratio” for
each PPI according to indication is calculated. Then, a
“market penetration percentage” for Nexium is esti-
mated for a period of three years for every dosage form
and indication. Overall PPI costs with or without Nex-
ium are calculated for the Greek population according to
indication. The overall cost difference depicts potential
cost savings.
RESULTS: The predicted Greek annual expenditure in
public prices for PPIs without Nexium is approximately
GRD 27.2 billion. In indications which lead to expendi-
tures of GRD 23 billion, Nexium could be prescribed
leading to a potential reduction in PPI costs of approxi-
mately 15% of the predicted expenditure without Nex-
ium. Percentage cost-savings are higher if Nexium re-
places certain PPIs, like branded omeprazole and
pantoprazole. It can be seen that the expected expendi-
tures after Nexium are lower than current costs for all
PPIs. This holds across all doses for each of the PPIs. A
proportional reduction is expected in overall units sold,
measured in 28–pack equivalents. Sensitivity analyses
based on varying penetration rates do not alter initial re-
sults significantly.
CONCLUSION: Nexium offers a disease management
approach leading to actual cost savings in PPI expendi-
tures in Greece. The saving impact is greater if highly
priced PPIs are replaced.
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OBJECTIVE: Health state utilities (‘utilities’) based on
patient preferences associated with heartburn do not ex-
ist in the published literature. The objectives of our study
were to assess utilities in GERD patients with heartburn
in Germany and Sweden, and to analyze if the severity
and frequency of heartburn and other patient characteris-
tics may predict utilities.
METHODS: One thousand eleven GERD patients with
heartburn as the predominant symptom were recruited
by their physicians and interviewed over the telephone.
Utilities were assessed using the standard gamble (SG),
time trade-off (TTO), EuroQol, and rating scale (RS) in-
struments. Another RS was used to assess the utility as
the patients thought it would be without heartburn. Data
were also collected about the severity (mild, moderate,
severe) and the annual number of days with heartburn
(‘frequency’). Linear regression analysis was used to esti-
mate the prediction models.
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RESULTS: The reported SG, TTO, EuroQol, and RS utili-
ties were on average 0.89, 0.88, 0.70, and 0.69. The RS util-
ity as it would be without heartburn was 0.84. The predic-
tion models showed that the EuroQol and RS utilities were
negatively related to heartburn severity and frequency. A
logarithmic transformation of heartburn frequency de-
scribed the functional relationship between frequency and
utilities best. The EuroQol, SG, and TTO utilities increased
with age. Women reported lower EuroQol and RS utilities
and higher SG utilities than men did. German patients re-
ported lower RS utilities than Swedish patients did. The pre-
dicted EuroQol (and RS) utilities by severity of heartburn
were 0.75 (0.72), 0.67 (0.67), and 0.50 (0.61).
CONCLUSION: Our results indicate that patients assign
substantial disability to heartburn. The results also indicate
that utilities may be predicted from heartburn severity and
frequency and other patient characteristics. The assessed
utilities and the prediction models may provide a basis for
future cost-utility analyses of GERD interventions.
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LONG TERM CLINICAL CONSEQUENCES OF 
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AFTER CATARACT SURGERY –– A MARKOV 
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OBJECTIVE: Posterior Capsular Opacification (PCO) is
the most frequent long-term complication of cataract sur-
gery with some different incidence rates across the intra-
ocular lenses (IOL). PCO is treated with Neodimium:Yag
(Nd:Yag) laser. The aim of this model was to evaluate the
clinical long-term consequences of Nd:Yag laser capsul-
otomy complications over the patient’s life.
METHODS: A 19-state Markov model was constructed
including the 14 states describing the Nd:Yag laser com-
plications reported in the literature: PCO; Nd:Yag laser;
post Nd:Yag laser; blindness and death. Probability to
die was modeled from national mortality tables as a poly-
nomial function of gender and age. Probability to become
blind was modeled as a function of age from literature
data. Incidence of Nd:Yag complications came from the
literature. The shape of the long term Nd:Yag laser use
incidence-survival curve was modeled from a cohort of
3335 patients with a maximum follow-up of 10 years.
Parameters of the modified Rayleigh function were esti-
mated according to least square mean method. Full sensi-
tivity analyses were conducted.
RESULTS: Switching a whole 70-year old population (1
male:1 female) from a 20% Nd:Yag laser incidence rate
of IOL at 3 years to 5% would avoid one chronic intra-
ocular pressure increase every 54 to 66 surgeries, one visual-
acuity decrease every 111 to 137 surgeries, one glaucoma
every 238 to 292 surgeries, one cystoid macular oedema
every 265 to 326 surgeries, one retinal detachment every
265 to 326 surgeries over the patient’s life. A three year
clinical study would only capture one third to one half of
the long term Nd:Yag adverse events.
CONCLUSION: Based on the results of this Markov
model, long term use of Nd:Yag laser being estimated on
a 10-year follow-up cohort, PCO rate is reduced, and
therefore the use of Nd:Yag laser might contribute to pre-
serving patient’s visual acuity over their full life.
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OBJECTIVE: The aim of this study was to compare the
costs and clinical consequences of olopatadine, a NCE
with a dual mechanism of action (anti-histamine and
mast cell stabilizer) with topical levocabastine for the
treatment of seasonal allergic conjunctivitis (SAC) in Bel-
gium, France, Germany, Netherlands, Norway, Portugal
and Sweden.
METHODS: A randomized, controlled, double-blind,
multi-country clinical trial compared the efficacy and
safety of olopatidine 0.1% bid and levocabastine 0.05%
qid. An economic comparison of first-line treatment fail-
ures with olopatadine versus levocabastine was modeled
using clinical trial results and a standard cost approach.
A societal perspective was adopted. Indirect resource uti-
lization was estimated from the clinical trial. Cost of fail-
ure was established from Pinto.
RESULTS: 210 patients (101 olopatadine, 109 levo-
cabastine) with SAC were treated over 42 days. At day
42, olopatadine-treated patients had a lower redness
score (P  0.05) while the difference in itching scores
was close to statistical significance (P  0.062). The first-
line treatment-failure rate was 15.8% less (P  .01) in ol-
opatadine-treated patients. Olopatadine patients had a
1.47 greater chance (P  .0001) of having a day without
symptoms. Olopatadine was well tolerated. Time lost due
to SAC was lower than 1 hour on average. Cost of failure
varied across countries from €48 to €72 . Savings per
episode due to first-line failures avoided with olopatadine
were €8.84 in Belgium, €10.97 in France, €10.94 in
Germany, €7.74 in NL, €7.61 in Norway, €10.65 in
Portugal and €11.33 in Sweden. Sensitivity analyses con-
firmed the robustness of our findings.
CONCLUSION: Based on results of a randomized clini-
cal trial, and resources and costs associated with failure
estimated from the literature, our model found that olo-
patadine is a cost-saving alternative to levocabastine and
provides more clinical benefits to patients. Results were
consistent over all study countries.
